Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study

Fig. 2

a Cell-free DNA concentrations at start of combined immunotherapy (x axis) and at first follow-up (3–4 weeks later, y axis). Patients were classified into three groups, depending on the change in their cell-free DNA concentration as increasing (increase of more than 50%), decreasing (decrease of more than 50%), or stable. The respective thresholds are marked by broken lines. Increase of cell-free DNA is observed more frequently in non-responders. The four highest values can be seen in the inserted image in the upper right corner. b ctDNA, measured by tumor-specific variant copies/ml of plasma at start of combined immunotherapy (x axis), and at first follow-up (3–4 weeks later, y axis). Increase of ctDNA is almost only observed in progressive patients. Please note that multiple patients had undetectable ctDNA at both time points and are not visible in the plot as separate points due to overplotting (2 for complete response, 4 for partial response, 3 for progress)

Back to article page